Fidson Healthcare approves ₦3.6bn dividend after hitting ₦119bn revenue mark
Fidson Healthcare Plc shareholders approved a dividend of ₦1.50 per 50 kobo ordinary share, amounting to ₦3.6 billion, at the virtual 27th Annual General Meeting held on Thursday, 30 July 2026. The company also announced revenue of ₦119.06 billion, becoming the first Nigerian pharmaceutical firm to surpass the ₦100 billion annual revenue milestone, and highlighted ongoing expansion projects that aim to make Fidson the largest and most sophisticated pharmaceutical manufacturer in Sub‑Saharan Africa.
This matters because the dividend rewards investors while the company retains funds for growth, signalling confidence in its prospects despite a challenging operating environment. Record revenue shows the sector’s potential and the impact of government policies supporting local drug makers. The planned expansion could improve medicine availability and lower costs nationwide, affecting anyone who relies on pharmaceuticals.
Shareholders should watch Fidson’s investor relations channels or the Nigerian Exchange for the exact dividend payment date and instructions for e‑dividend distribution. Consumers and health workers can anticipate broader access to locally produced medicines as the firm’s capacity expands, potentially influencing prices and supply chains.